Exercise intolerance in chronic heart failure - Skeletal muscle dysfunction and potential therapies

Circulation Journal

Volumn 77, Issue 2, 2013, Pages 293-300

  Okita, Koichi ^a   Kinugawa, Shintaro ^b   Tsutsui, Hiroyuki ^b  

^a HOKUSHO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Exercise tolerance; Exercise training; Heart failure; Myopathy; Skeletal muscle

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MYOSIN HEAVY CHAIN; PLACEBO; REACTIVE OXYGEN METABOLITE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BICYCLE ERGOMETRY; BIOCHEMISTRY; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE CARDIOMYOPATHY; EXERCISE; EXERCISE TOLERANCE; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPOXIA; INFLAMMATION; MALNUTRITION; MUSCLE METABOLISM; MYOPATHY; NONHUMAN; OXIDATIVE STRESS; PERFUSION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKELETAL MUSCLE;

CHRONIC DISEASE; EXERCISE; EXERCISE TOLERANCE; HEART FAILURE; HUMANS; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 84873835755     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1235     Document Type: Review

References (93)

1. Maskin CS, Forman R, Sonnenblick EH, Frishman WH, LeJemtel TH. Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. Am J Cardiol 1983; 51: 177-182.
2. Wilson JR, Martin JL, Ferraro N. Impaired skeletal muscle nutritive flow during exercise in patients with congestive heart failure: Role of cardiac pump dysfunction as determined by the effect of dobutamine. Am J Cardiol 1984; 53: 1308-1315.
3. Rogers FJ. The muscle hypothesis: A model of chronic heart failure appropriate for osteopathic medicine. J Am Osteopath Assoc 2001; 101: 576-583.
4. Nilsson KR, Duscha BD, Hranitzky PM, Kraus WE. Chronic heart failure and exercise intolerance: The hemodynamic paradox. Curr Cardiol Rev 2008; 4: 92-100.
5. Wiener DH, Fink LI, Maris J, Jones RA, Chance B, Wilson JR. Abnormal skeletal muscle bioenergetics during exercise in patients with heart failure: Role of reduced muscle blood flow. Circulation 1986; 73: 1127-1136.
6. Mancini DM, Coyle E, Coggan A, Beltz J, Ferraro N, Montain S, et al. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic HF. Circulation 1989; 80: 1338-1346.
7. Nagai T, Okita K, Yonezawa K, Yamada Y, Hanada A, Ohtsubo M, et al. Comparisons of the skeletal muscle metabolic abnormalities in the arm and leg muscles of patients with chronic heart failure. Circ J 2004; 68: 573-579.
8. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long term heart failure. Circulation 1990; 81: 518-527.
9. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in chronic HF. Circulation 1992; 85: 1751-1759.
10. Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in HF. Circulation 1992; 85: 1364-1373.
11. Massie BM, Simonini A, Sahgal P, Wells L, Dudley GA. Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive HF. J Am Coll Cardiol 1996; 27: 140-145.
12. Vescovo G, Serafini F, Facchin L, Tenderini P, Carraro U, Dalla Libera L, et al. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: Differences with disuse atrophy as assessed on microbiopsies by a new electrophoretic micromethod. Heart 1996; 76: 337-343.
13. Clark AL, Poole-Wilson PA, Coats AJS. Exercise limitation in chronic heart failure: Central role of the periphery. J Am Coll Cardiol 1996; 28: 1092-1102.
14. Middlekauff HR. Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail 2010; 3: 537-546.
15. Okita K, Yonezawa K, Nishijima H, Hanada A, Ohtsubo M, Kohya T, et al. Skeletal muscle metabolism limits exercise capacity in patients with chronic heart failure. Circulation 1998; 98: 1886-1891.
16. Franssen FM, Wouters EF, Schols AM. The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr 2002; 21: 1-14.
17. Duscha BD, Schulze PC, Robbins JL, Forman DE. Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Heart Fail Rev 2008; 13: 21-37.
18. Dalla Libera L, Vescovo G, Volterrani M. Physiological basis for contractile dysfunction in heart failure. Curr Pharm Des 2008; 14: 2572-2581.
19. Ventura-Clapier R, De Sousa E, Veksler V. Metabolic myopathy in heart failure. News Physiol Sci 2002; 17: 191-196.
20. Jondeau G, Katz SD, Zohman L, Goldberger M, McCarthy M, Bourdarias JP, et al. Active skeletal muscle mass and cardiopulmonary reserve: Failure to attain peak aerobic capacity during maximal bicycle exercise in patients with severe congestive heart failure. Circulation 1992; 86: 1351-1356.
21. Kayser B. Exercise starts and ends in the brain. Eur J Appl Physiol 2003; 90: 411-419.
22. Harris RC, Edwards RH, Hultman E, Nordesjö LO, Nylind B, Sahlin K. The time course of phosphorylcreatine resynthesis during recovery of the quadriceps muscle in man. Pflügers Arch 1976; 367: 137-142.
23. Okita K, Nishijima H, Yonezawa K, Ohtsubo M, Hanada A, Kohya T, et al. Skeletal muscle metabolism in maximal bicycle and treadmill exercise distinguished by using in-vivo metabolic freeze method and phosphorus-31 magnetic resonance spectroscopy in normal men. Am J Cardiol 1998; 81: 106-109.
24. Wilson JR, Groves J, Rayos G. Circulatory status and response to cardiac rehabilitation in patients with heart failure. Circulation 1996; 94: 1567-1572.
25. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010; 122: 173-183.
26. Tabet JY, Meurin P, Beauvais F, Weber H, Renaud N, Thabut G, et al. Absence of exercise capacity improvement after exercise training program: A strong prognostic factor in patients with chronic heart failure. Circ Heart Fail 2008; 1: 220-226.
27. Stratton JR, Dunn JF, Adamopoulos S, Kemp GJ, Coats AJ, Rajagopalan B. Training partially reverses skeletal muscle metabolic abnormalities during exercise in heart failure. J Appl Physiol 1994; 76: 1575-1582.
28. Ohtsubo M, Yonezawa K, Nishijima H, Okita K, Hanada A, Kohya T, et al. Metabolic abnormality of calf skeletal muscle is improved by localised muscle training without changes in blood flow in chronic heart failure. Heart 1997; 78: 437-443.
29. Man WD, Kemp P, Moxham J, Polkey MI. Skeletal muscle dysfunction in COPD: Clinical and laboratory observations. Clin Sci (Lond) 2009; 117: 251-264.
30. Zattara-Hartmann MC, Badier M, Guillot C, Tomei C, Jammes Y. Maximal force and endurance to fatigue of respiratory and skeletal muscles in chronic hypoxemic patients: The effects of oxygen breathing. Muscle Nerve 1995; 18: 495-502.
31. Rubin SA, Brown HV, Swan HJ. Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment. Circulation 1982; 66: 143-148.
32. Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 2005; 37: 1938-1947.
33. Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W, et al. Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone. J Am Coll Cardiol 2001; 38: 443-452.
34. Schulze PC, Späte U. Insulin-like growth factor-1 and muscle wasting in chronic heart failure. Int J Biochem Cell Biol 2005; 37: 2023-2035.
35. Acevedo M, Corbalán R, Chamorro G, Jalil J, Nazzal C, Campusano C, et al. Administration of growth hormone to patients with advanced cardiac heart failure: Effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol 2003; 87: 185-191.
36. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hänlein D, Willenbrock R, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-1237.
37. Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, et al. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 2009; 94: 3329-3336.
38. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, et al. Anabolic deficiency in men with chronic heart failure: Prevalence and detrimental impact on survival. Circulation 2006; 114: 1829-1837.
39. Iellamo F, Rosano G, Volterrani M. Testosterone deficiency and exercise intolerance in heart failure: Treatment implications. Curr Heart Fail Rep 2010; 7: 59-65.
40. Iellamo F, Volterrani M, Caminiti G, Karam R, Massaro R, Fini M, et al. Testosterone therapy in women with chronic heart failure: A pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010; 56: 1310-1316.
41. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart 2004; 90: 446-447.
42. Malkin CJ, Pugh PJ, West JN, Van Beek EJR, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57-64.
43. Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail 2007; 9: 44-50.
44. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919-927.
45. Dalla Libera L, Vescovo G. Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: A chimaeric view of inflammation? Curr Opin Clin Nutr Metab Care 2004; 7: 435-441.
46. Attaix D, Ventadour S, Codran A, Béchet D, Taillandier D, Combaret L. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 2005; 41: 173-186.
47. Ventadour S, Attaix D. Mechanisms of skeletal muscle atrophy. Curr Opin Rheumatol 2006; 18: 631-635.
48. McKinnell IW, Rudnicki MA. Molecular mechanisms of muscle atrophy. Cell 2004; 119: 907-910.
49. Chamberlain JS. Cachexia in cancer zeroing in on myosin. N Engl J Med 2004; 351: 2124-2125.
50. Vescovo G, Dalla Libera L. Skeletal muscle apoptosis in experimental heart failure: The only link between inflammation and skeletal muscle wastage? Curr Opin Clin Nutr Metab Care 2006; 9: 416-422.
51. Dalla Libera L, Ravara B, Volterrani M, Gobbo V, Della Barbera M, Angelini A, et al. Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure. Am J Physiol Cell Physiol 2004; 286: C138-C144.
52. Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibit ubiquitin-mediated muscle atrophy in chronic leftventricular dysfunction. Circ Res 2005; 97: 418-426.
53. Adams V, Jiang H, Yu J, Mobius-Winkler S, Fiehn E, Linke A, et al. Apoptosis in skeletal myocytes of patients with chronic HF is associated with exercise intolerance. J Am Coll Cardiol 1999; 33: 959-965.
54. Vescovo G, Volterrani M, Zennaro R, Sandri M, Ceconi C, Lorusso R, et al. Apoptosis in the skeletal muscle of patients with heart failure: Investigation of clinical and biochemical changes. Heart 2000; 84: 431-437.
55. Dalla Libera L, Sabbadini R, Renken C, Ravara B, Sandri M, Betto R, et al. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. J Mol Cell Cardiol 2001; 33: 1871-1878.
56. Picano E, Morales MA, del Ry S, Sicari R. Innate inflammation in myocardial perfusion and its implication for heart failure. Ann NY Acad Sci 2010; 1207: 107-115.
57. Yndestad A, Damås JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure: The whys and wherefores. Heart Fail Rev 2006; 11: 83-92.
58. Muller-Wedan U, Werdan K. Immune modulation by catecholamines: A potential mechanism of cytokine release in HF? Herz 2000; 25: 271-273.
59. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-534.
60. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241.
61. Adams V, Nehrhoff B, Spate U, Linke A, Schulze PC, Baur A, et al. Induction of iNOS expression in skeletal muscle by IL-1beta and NFkappaB activation: An in vitro and in vivo study. Cardiovasc Res 2002; 54: 95-104.
62. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: An overview. Heart 2004; 90: 464-470.
63. Li YP, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 1998; 12: 871-880.
64. Spate U, Schulze PC. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 2004; 7: 265-269.
65. Combes A, Frye CS, Lemster BH, Brooks SS, Watkins SC, Feldman AM, et al. Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. Pflugers Arch 2002; 445: 246-256.
66. Heistad DD, Wakisaka Y, Miller J, Chu Y, Pena-Silva R. Novel aspects of oxidative stress in cardiovascular diseases. Circ J 2009; 73: 201-207.
67. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and mitochondrial DNA damage in heart failure. Circ J 2008; 72(Suppl A): A-31-A-37.
68. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411-418.
69. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011; 301: H2181-H2190.
70. Fujita S, Ikeda Y, Miyata M, Shinsato T, Kubozono T, Kuwahata S, et al. Effect of Waon therapy on oxidative stress in chronic heart failure. Circ J 2011; 75: 348-356.
71. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: Role of oxidative stress. Circ Res 2000; 87: 392-398.
72. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Shiomi T, Wen J, et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 2001; 104: 134-136.
73. Kojda G, Hambrecht R. Molecular mechanisms of vascular adaptations to exercise: Physical activity as an effective antioxidant therapy? Cardiovasc Res 2005; 67: 187-197.
74. Sonnenblick EH, LeJemtel TH. Pathophysiology of congestive heart failure: Role of angiotensin-converting enzyme inhibitors. Am J Med 1989; 87: 88S-91S.
75. Ostrander EA, Huson HJ, Ostrander GK. Genetics of athletic performance. Annu Rev Genomics Hum Genet 2009; 10: 407-429.
76. Montgomery HE, Marshall R, Hemingway H, Myerson S, Clarkson P, Dollery C, et al. Human gene for physical performance. Nature 1998; 393: 221-222.
77. Sukhanov S, Semprun-Prieto L, Yoshida T, Michael Tabony A, Higashi Y, Galvez S, et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci 2011; 342: 143-147.
78. Dalla Libera L, Ravara B, Gobbo V, Danieli Betto D, Germinario E, Angelini A, et al. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. J Mol Cell Cardiol 2005; 38: 803-807.
79. Davies EJ, Moxham T, Rees K, Singh S, Coats AJ, Ebrahim S, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail 2010; 12: 706-715.
80. Piepoli MF, Conraads V, Corrà U, Dickstein K, Francis DP, Jaarsma T, et al. Exercise training in heart failure: From theory to practice: A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 2011; 13: 347-357.
81. Nishi I, Noguchi T, Iwanaga Y, Furuichi S, Aihara N, Takaki H, et al. Effects of exercise training in patients with chronic heart failure and advanced left ventricular systolic dysfunction receiving β-blockers. Circ J 2011; 75: 1649-1655.
82. Downing J, Balady GJ. The role of exercise training in heart failure. J Am Coll Cardiol 2011; 58: 561-569.
83. Dimmeler S, Zeiher AM. Exercise and cardiovascular health: Get active to "AKTivate" your endothelial nitric oxide synthase. Circulation 2003; 107: 3118-3120.
84. Nair AP, Timoh T, Fuster V. Contemporary medical management of systolic heart failure. Circ J 2012; 76: 268-277.
85. Vescovo G, Dalla Libera L, Serafini F, Leprotti C, Facchin L, Volterrani M, et al. Improved exercise tolerance after losartan and enalapril in heart failure: Correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 1998; 98: 1742-1749.
86. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, et al. Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. Circulation 2001; 103: 2195-2200.
87. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005; 115: 451-458.
88. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-569.
89. Sabbah HN. Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev 2004; 9: 91-97.
90. Kubo T, Azevedo ER, Newton GE, Picton P, Parker JD, Floras JS. Beta-blockade restores muscle sympathetic rhythmicity in human heart failure. Circ J 2011; 75: 1400-1408.
91. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, et al. Testosterone supplementation in heart failure: A metaanalysis. Circ Heart Fail 2012; 5: 315-321.
92. Patwala AY, Woods PR, Sharp L, Goldspink DF, Tan LB, Wright DJ. Maximizing patient benefit from cardiac resynchronization therapy with the addition of structured exercise training: A randomized controlled study. J Am Coll Cardiol 2009; 53: 2332-2339.
93. Middlekauff HR. How does cardiac resynchronization therapy improve exercise capacity in chronic heart failure? J Card Fail 2005; 11: 534-541.